Navigation Links
Novartis's Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
Date:7/29/2013

BURLINGTON, Mass., July 29, 2013 /PRNewswire/ --  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical trial data and thought leader opinion, Novartis's novel vasodilative therapy serelaxin has the potential to gain acceptance among cardiologists for the treatment of acute heart failure, given that it is predicted to reduce mortality and prevent worsening renal function. While cardiologists are most compelled by drugs that reduce patient mortality, the high price of novel acute heart failure treatments could offset cardiologist receptivity to such agents. Payers also indicate that they would only accommodate such high price premiums in the presence of substantial improvements in efficacy. Cardiorentis's ularitide is similarly predicted to reduce mortality as well as offer other improvements in efficacy and safety compared to current therapies.     

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Acute Heart Failure: Can the Novel Vasodilators Serelaxin and Ularitide Fulfill the Unmet Needs Highlighted by Cardiologists? also finds that U.S. cardiologists regard reductions in acute heart failure hospital readmissions as an equally pressing unmet need to reducing patient mortality. However, none of the current or emerging therapies are expected to address the issue of patient rehospitalization. Although serelaxin was associated with a non-significant increase in rehospitalization in patient trials, this agent still received the highest preference share when compared to ularitide and Scios/Johnson & Johnson's Natrecor in Decision Resources' target product profile simulator.

The findings also reveal that all of the emerging acute heart failure therapies are set to surp
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
2. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
3. Cosmetic Surgery Solicitors Warn of Potential Risks Posed by Dermal Fillers
4. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
5. AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
6. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
7. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
8. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
9. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
11. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Kannalife Sciences, Inc. ("Kannalife") announces that Dr. ... Board to assist the Company in the advancement of ... cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy ... conducting the full autopsy of Mike Webster , ... Pittsburgh Steelers. It was through his examination of ...
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... , March 4, 2015  ECR Booth #317/Expo ... ) is showcasing a full spectrum of X-ray imaging ... quality, reduce costs, and enable greater patient throughput for ... imaging systems.  These solutions are on display at the ... Vienna, Austria this week.   ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
... 2011 Argos Therapeutics, Inc. today announced that its late ... awarded the Nobel Prize in medicine for the discovery of ... Dr. Steinman,s discovery of dendritic cells and his research ... in adaptive immunity have led to the development of Argos, ...
... Today, Children,s Hospital at Scott & White , the ... facility between Dallas and Austin, opened its doors to patients. ... state-of-the-art Simulation Center for a mock transport of "patients" from ... White Hospital-Temple, before moving patients to the new Children,s Hospital ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2Children's Hospital at Scott & White Opens 2Children's Hospital at Scott & White Opens 3Children's Hospital at Scott & White Opens 4
(Date:3/4/2015)... (PRWEB) March 04, 2015 RapidScale, a ... in Las Vegas, Nevada, on March 16th-18th. They are ... will have some of its top engineering executives in ... in the RapidScale solution set. Attendees include William Hiatt, ... Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
(Date:3/4/2015)... SIGVARIS proved innovative when they ... compression therapy collection designed exclusively for men. Building ... is proud to announce the launch of three additional ... from a unique, extremely fine synthetic fiber, MIDTOWN MICROFIBER ... and thigh-highs offer a tailored look that is perfect ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... discussion leaders for its upcoming fifth annual Advanced ... Paris, France. The event this year will feature ... than 20 of the field’s leading companies and ... together top executives and clinical researchers from the ...
(Date:3/4/2015)... Jeannie Mai, TV personality, fashion maven, and co-host of ... the print publication. Mai embraces the overall theme of the ... clothes and personal care products. In an exclusive interview, Olympic ... an organic diet. She mentions, “Having an organic lifestyle has ... also now as I’m a full time student at New ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 i2i ... been selected by Chase Brexton Health Care, a ... today. , Chase Brexton provides comprehensive primary care, ... 30,000 patients across seven clinics in the greater ... of electronic medical records, the organization has always ...
Breaking Medicine News(10 mins):Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 2Health News:The Alliance for Regenerative Medicine Announces Agenda for Upcoming Advanced Therapies Summit 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3
... eating dietary fiber specifically from fruits and cereals lowers ... // a connection between higher intake of fiber and ... actually looked at the dietary fiber from different sources ... study researchers analyzed several studies to determine whether the ...
... , medication errors that occur in pediatric intensive care units ... ,Researchers studied more than 11,800 children who were admitted into ... errors. They defined an error as any preventable event that ... medical errors were reported during the course of the study. ...
... A new study shows weight gain after age 18 can ... women who // are not taking hormone replacement therapy. ... to 74, by asking them about their weight at age ... been periodically asked to provide updates on their weight, in ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... a recent study conducted researchers suggest that kids who ... having their tonsils and adenoids out. ,Adenotonsillectomy is ... of the time, it is performed to treat recurring ... have also used the surgery to treat obstructive sleep ...
... strikes men between 20 and 34 years old. Advances ... improved survival rate from the cancer, but since men ... the effect of the cancer and its treatment on ... treatment reduces fertility, others have found fertility rates unchanged. ...
Cached Medicine News:
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
...
Tips are sharp on both sides to puncture, cut and tear the capsule...
Medicine Products: